Summary:

India's pharmaceutical sector, the world's largest provider of generic medicines, is expanding rapidly, with exports growing at 9%—nearly double the global average. It meets 20% of global demand, including 40% of the US's generic medicine requirements and 25% of the UK market. India now leads in FDA-registered manufacturing sites, with improved compliance and a 30-35% cost advantage over US and European firms.

The pharmaceutical industry has grown at an 8% CAGR, strengthening API and biotechnology capabilities. Advanced therapeutics such as mRNA, gene therapies, and monoclonal antibodies are expanding at a 13-14% CAGR, outpacing traditional pharmaceuticals. AI and generative AI could generate up to US$ 110 billion in revenue, improve margins by 4-7%, and increase productivity by 50%. CDMOs have invested US$ 650 million, further solidifying India's global pharmaceutical leadership.

Source: IBEF

Disclaimer:The information on this website comes from the India Brand Equity Foundation (IBEF), a reliable source for thorough insights into numerous areas of the Indian economy. While we aim to offer accurate and up-to-date information, the views, opinions, and analyses stated herein are solely those of the authors and contributors and do not necessarily represent IBEF's official stance or position. Readers should check information from credible sources and use their own discretion when relying on content provided on this site. We assume no responsibility or liability for the supplied content, including its accuracy, completeness, and usefulness.